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Abstract
Background: Graves’ disease is an autoimmune thyroid disease of complex inheritance. Multiple genetic
susceptibility loci are thought to be involved in Graves’ disease and it is therefore likely that these can be identified
by genome wide association studies. This study aimed to determine if a genome wide association study, using a
pooling methodology, could detect genomic loci associated with Graves’ disease.
Results: Nineteen of the top ranking single nucleotide polymorphisms including HLA-DQA1 and C6orf10, were
clustered within the Major Histo-compatibility Complex region on chromosome 6p21, with rs1613056 reaching
genome wide significance (p = 5 × 10−8). Technical validation of top ranking non-Major Histo-compatablity complex
single nucleotide polymorphisms with individual genotyping in the discovery cohort revealed four single
nucleotide polymorphisms with p ≤ 10−4. Rs17676303 on chromosome 1q23.1, located upstream of FCRL3, showed
evidence of association with Graves’ disease across the discovery, replication and combined cohorts. A second
single nucleotide polymorphism rs9644119 downstream of DPYSL2 showed some evidence of association
supported by finding in the replication cohort that warrants further study.
Conclusions: Pooled genome wide association study identified a genetic variant upstream of FCRL3 as a
susceptibility locus for Graves’ disease in addition to those identified in the Major Histo-compatibility Complex. A
second locus downstream of DPYSL2 is potentially a novel genetic variant in Graves’ disease that requires further
confirmation.
Keywords: Graves’ disease, Genome-wide association study, Pooled blood
Background
Graves’ disease (GD) is an autoimmune thyroid disease
which typically presents as thyrotoxicosis and goitre;
other clinical findings include Graves’ orbitopathy, der-
mopathy and acropachy. The incidence rate of GD is 15
per 100, 000 persons per year with an overall mean
prevalence of 1152 per 100, 000 population in the
United States [1, 2]. Women are disproportionately more
affected with the female to male ratio reported at 7.3:1
[1]. The disease also occurs in children at one tenth the
prevalence rate of all ages [1].
GD is a complex disease with a strong familial predis-
position; [3–7] the triggers are poorly understood but
various environmental factors were linked to onset of
GD such as stress, smoking and Yersinia infection in
genetically susceptible individuals [8, 9]. GD shows a
strong familial predisposition. The concordance rate for
GD in monozygotic twins is significantly higher than di-
zygotic twins and model-fitting analysis predicted that
genetic factors account for 79 % of disease heritability in
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twins [10]. With a concordance rate of 22–35 % for
monozygotic twins, environmental and modifier factors
are likely to play a key role [10, 11]. Clustering of GD
with other autoimmune conditions including type I dia-
betes mellitus, myasthenia gravis, polymyositis, lupus ery-
thematosus and Addison’s disease suggest genes regulating
the immune system shared by these diseases might also
contribute towards the genetic susceptibility for GD [3].
The genetic susceptibility of GD can be broadly cate-
gorized into genes involved in immune regulation, and
thyroid specific genes. Genes confirmed to be associated
with GD include the following: multiple loci within the
Human leukocyte antigen (HLA) I and II region, as well
as non-HLA loci CTLA4, PTPN22, CD40, IL2A, FCRL3
and TSHR [12–26]. The contributions from each of
these genetic variants are modest. From candidate gene
studies, HLA class II alleles DRB1*03(DR3), DQA1*0501,
DQB1*02 were significantly associated with GD with
odd ratios of 2 to 3 for DR3 [5, 15, 27, 28]. CTLA4
A49G, and CT60 3′UTR polymorphisms were more fre-
quent in GD with an odds ratio of 1.4 to 2, [12, 13, 29–31]
and association with PTPN22 polymorphism has an odds
ratio of 1.5 to 1.9 [14, 16, 17].
Genome wide association studies (GWAS) have repli-
cated earlier candidate gene study findings and identified
additional new genetic loci. The earliest GWAS studies on
autoimmune thyroid disease showed association of GD
with multiple loci within the HLA class I and II regions,
and also in TSHR and FCRL3 [26, 32]. More recently two
new risk loci for GD, the RNASET2-FGFR1OP-CCR6 re-
gion at 6q27 and an intergenic region at 4p14 were re-
ported, along with confirmation of positive association of
GD with SNPs in HLA-DPB1, TSHR, CLTA4 and FCRL3
[33]. Using a custom array, association of SNPs near
PTPN22, CTLA4, TSHR, RNASET2-FGFR1OP-CCR6 loci
with GD were replicated, and seven novel susceptibility
loci, MMEL1, LPP, BACH2, PRICKLE1, ITGAM,
rs1534422 at 2p25.1 and rs4409785 at 11q21 were identi-
fied but the results require confirmation in replication
studies [24].
A pooled GWAS strategy can effectively identify gene
variants in multiple diseases. Using relatively small num-
bers of cases and controls, pooled GWAS has previously
been used to identify the known susceptibility loci CFH
and ARMS2/HTRA1 in age related macular degeneration
and LOXL1 in pseudoexfoliation syndrome [34]. A
pooled DNA study has also identified a new susceptibil-
ity locus, HGF, in keratoconus (a progressive corneal de-
generation) and additional novel candidate genes related
to platelet reactivity in diabetic patients [34–36]. The
study design must be carefully considered to include
multiple pools to minimise pooling errors and an appro-
priate array platform to extract maximal available infor-
mation from the pooled DNA [37, 38].
The aim of this study was to determine if GWAS using
DNA pooling methodology could replicate genomic loci
associated with GD and discover new genetic loci.
Methods
Definition of Graves’ disease
GD cases were participants with biochemically con-
firmed hyperthyroidism on thyroid function tests; and
had either the presence of Graves’ orbitopathy, or posi-
tive thyrotropin receptor (TSHR) antibodies or uniform
increase in uptake on technetium-99 m pertechnetate
thyroid scan.
Discovery cohort
The Australian Thyroid-associated Orbitopathy Research
(ATOR) discovery cohort consisting of 412 GD cases
with and without Graves’ orbitopathy of European des-
cent was recruited from endocrinology and ophthalmol-
ogy clinics in the hospitals and private practices from
Victoria and South Australia.
A total of 498 controls were recruited from two
Australian populations. These comprised 198 adult
patients with keratoconus, a non-autoimmune eye dis-
ease unrelated to GD, who were recruited from eye
clinics in Melbourne, and 300 healthy controls aged
over 50 years recruited from retirement villages and
the general community in South Australia. The con-
trol cohort was not actively screened for GD, but
none of the controls reported having this condition.
Replication cohort
An independent group of 539 GD cases and 1230 controls
were recruited to form a replication cohort. The GD cases
were new cases recruited into the ATOR cohort (n = 373)
from Melbourne, and endocrine and ophthalmology
clinics from Western Australia (n = 166). The controls
were research participants of European descent with eye
diseases without recognizable association with GD or
other autoimmune diseases (angle closure glaucoma or
suspect, pigment dispersion syndrome, steroid responsive
ocular hypertension, myopia and keratoconus) recruited
in a collaborative effort from South Australia and Victoria
to study the genetics of these eye diseases (age ranging
from 9 to 92 years).
DNA pooling for GWAS study
Two methods of DNA pooling were used. For freshly
collected samples, whole blood was pooled directly (pool 1)
and for archived DNA samples, equimolar DNA pools
were created (pools 2 and 3). Venous blood or DNA ali-
quots from all participants were thawed for 3 h before con-
struction of 3 pool comparisons. Pool number 1 contained
154 GD cases and 198 controls, pool number 2 had 218
GD cases and 213 controls, and pool number 3 had 40 GD
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cases and 87 controls, giving a total of 412 cases and 498
controls from the discovery cohort. For pool 1, 100 μl of
whole blood from each sample was mixed with protease
and lysis buffer, vortexed and incubated, then samples were
combined in one tube for whole blood pool construction, 1
tube each for cases and controls. DNA was extracted from
the whole blood pool by using QIA-amp DNA blood maxi
kit (Qiagen, Valencia, CA, USA) according to the manufac-
turer’s protocol. For pool 2 and 3 samples, whole blood
was lysed and DNA was extracted from each sample.
Equimolar DNA pools were constructed in duplicate by
step-wise dilutions of genomic DNA using QIA-amp
DNA blood maxi kit (Qiagen, Valencia, CA, USA) to
75 ng/μl. We used Fluoroskan Ascent microplate
fluorometer (ThermoFisher Scientific, Waltham, MA,
USA) coupled with Picogreen reagents (Invitrogen,
Carlsbad, CA) for DNA quantitation. Comparisons
were made to a standard curve generated from serial
dilutions of Lambda DNA (Invitrogen, Carlsbad, CA).
A total of 451 ng of DNA from each sample was added
to the equimolar DNA pool.
Pooling error
Previous studies showed that the majority of pooling er-
rors arise from errors on the arrays rather than pool
construction errors, [39] hence in this pooling design,
multiple Illumina HumanOmni5-Quad arrays were used
for each pool to reduce array errors. The pooling stand-
ard deviation is very small for the Illumina bead arrays,
pooling standard deviation for HumanHap300 was esti-
mated between 0.007 and 0.011, [38] and variance for
the 1M array was 6.8 × 10−5 [34]. This encompasses both
assays and pool construction errors. The Illumina
HumanOmni5-Quad beadchip array supersedes its prede-
cessor arrays; the HumanHap300 and 1M array, by virtue
of its comprehensive coverage of the human genome but
is similar in the way of the bead array design.
Pooled genotyping and analysis
Genome-wide genotyping was conducted at Queensland
Institute of Medical Research (QIMR) Berghofer Medical
Research Institute, using HumanOmni5-Quad beadchip
microarray (Illumina, San Diego, CA, USA) which con-
tained approximately 4.3 million markers. Three case and
control pools, each replicated 2 to 4 times to minimise
measurement error, were generated for comparisons.
The output of the raw beadscores from Illumina Bead-
station were subjected to a series of data cleaning and
quality control measures, as described previously for
array-based DNA pooling studies [38, 40, 41]. SNPs with
minor allele frequency (MAF) greater than 1 % from the
reference panel of EUR samples in the 1000 Genomes
Project were retained for subsequent analysis (i.e. 2.5
million SNPs). We excluded SNPs with more than 10 %
negative beadscores, and SNPs with the sum of mean
red and green scores smaller than 1200 across each
array. A correction factor (corr) was calculated to rescale
the green beadscore to calibrate the mean value of the
pooling allele frequency (PAF) at 0.5 over all SNPs on
each strand of the array. The PAF was computed based
on the raw red intensities and the corrected green inten-
sities as PAF = red/(red + green/corr) [40]. We further
filtered non-autosomal SNPs and any SNPs with a signifi-
cant variance difference between cases and controls.
A final set of autosomal SNPs meeting the following
criteria: (1) contain sufficient number of probes (i.e.,
over ½ of expected number of probes for SNPs with
MAF 1–5 %, or over 1/3 of expected number of probes
for SNPs with MAF >5 %; (2) display no larger than 0.3
differences between PAF and reference allele frequency
from EUR samples in the 1000 Genomes Project were
taken forward for association testing. After data cleaning
and quality control, 2.2M SNPs were left for association
testing. A linear model was used to test for allelic associ-
ation in the three case-control pools from GD discovery
cohort. The test statistic corrected for pooling error was
used to rank SNPs; with p values derived from chi-
squared distribution with 1 ° of freedom to assess the
significance of allele frequency difference between cases
and controls. We then conducted a meta-analysis
weighted by inverse variance to combine the results of
the three case-control pool comparisons. The top-
ranking SNPs in the meta-analysis were counter checked
for proxies (i.e., linkage disequilibrium r2 >0.5 with the
index SNPs in the EUR populations). If proxy SNPs were
available, they should also show evidence of association
to be considered valid. A genome-wide significance
threshold was set at 5 × 10−8 to account for multiple
testing but SNPs with p < 1 × 10−6 were also included for
further evaluation.
Individual genotyping and analysis
Top-ranked non-major histo-compatability complex
(MHC) SNPs with p-value ≤1 × 10−6 were selected for
technical validation genotyping in individual DNA sam-
ples that made up the pool as well as for genotyping in
the replication cohorts. The top ranking SNPs were indi-
vidually genotyped in the discovery cohort in 412 GD
cases and 480 normal controls. A subset of 18 controls
had insufficient residual samples for individual genotyp-
ing, hence the discrepancy in the final pooling and valid-
ation sample sizes.
Thirteen SNPS were genotyped on iPLEX Gold assay
(Sequenom, San Diego, CA, USA) by using Sequenom
MassARRAY® Analyzer in two batches. The ATOR dis-
covery cohort and Western Australia replication cohort
genotyping was performed at the Australian Genome
Research Facility (Brisbane, Australia) and the ATOR
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replication cohort at GeneWorks Pty Ltd (Adelaide,
Australia). The allele association analysis was performed
using chi-square test (−−assoc) in PLINK, [42] inde-
pendently for technical validation in the ATOR pooled
discovery cohort, the replication cohorts and the overall
in the discovery and replication cohorts. The odds ratio
and 95 % confidence interval for allelic association was
further adjusted for covariates age and sex using logistic
regression analysis (−−logistic −−covar). SNPs with p ≤
1 × 10−4 were considered validated in validation genotyp-
ing. For replication genotyping, p <0.05 was considered
significant.
Results
The GD cases were predominantly female and younger
when compared with controls (Table 1), hence subse-
quent individual genotyping analysis was adjusted for
age and sex.
In the discovery GWAS, 19 of the top 30 ranking
SNPs clustered within the MHC region on chromosome
6p21 including rs9272937 in HLA-DQA1 (p 10−7), two
SNPs within C6orf10 (p 10−7), and rs1613056 reaching
genome wide significance (p = 5 × 10−8) (Additional file 1:
Table S1). One SNP, rs9676286 on chromosome 19,
reached genome-wide significance in the pooled GWAS
(p = 1.08 × 10−8) for association with GD. However
rs9676286 was not as strongly supported when we con-
ducted technical validation genotyping of the individual
DNA samples from the pools (p = 5.54 × 10−3).
An additional 12 top ranked non-MHC SNPs suggestive
of association (p ~ 10−6) were also selected for validation.
Of these, four SNPs showed evidence of association with
p < 1 × 10−4 when we conducted technical validation geno-
typing in the individual DNA samples. They are
rs1469893 on chr 15, rs17676303 on chr 1, rs78542322 on
chr 6 and rs62469516 on chr 7 (Table 2). Amongst these
four, rs1767303 was most strongly associated with GD
with a P value at 1.14 × 10−8 (OR = 2.05, 95 % CI
1.57–2.67). When correlating odds ratio of effect allele fre-
quencies in pooled GWAS with individual validation
genotyping, the results showed strong correlation (r =
0.89, p <0.001) (Additional file 2: Figure S1).
Genotyping in the replication cohort showed positive
association of GD with rs17676303, located upstream of
FCRL3 on chromosome 1q23.1 (OR = 1.22, 95 % CI
1.01–1.46, p = 0.04). The minor T allele was more fre-
quent in GD cases than in normal controls (OR = 1.42,
95 % CI 1.22–1.64, p = 3.41 × 10−6) in the combined dis-
covery and replication cohorts, adjusted for sex and age.
Rs62469516, rs1469893 and rs78542322 minor alleles
were not associated with GD in the replication cohort,
or the combined cohorts (Table 3).
We further examined the relationship between SNP
rs17676303 and other annotated SNPs in FCRL3 gene or
its promoter region, namely rs7528684, rs3761969 and
rs11264798, which have previously been identified as
positively associated with GD, rheumatoid arthritis and
systemic lupus erythematosus [25, 33, 43]. All three
SNPs previously associated with GD showed high link-
age disequilibrium with rs17676303 in the Caucasian
HapMap population (Table 4). The result suggests that
these SNPs reported with various auto-immune diseases
may be tagging the same functional genetic variants
around the FCRL3 gene locus.
A second SNP, rs9644119, located downstream of
DPYSL2 on chromosome 8p21 is highly ranked for its
association with GD in pooled GWAS with a P value ap-
proaching genome wide significance (p = 9.10 × 10−8).
The association was not validated in the discovery co-
hort and for the combined cohort the association with
GD is less strong than the discovery pooled GWAS
would suggest (p = 4.02 × 10−3). In the replication cohort,
the minor T allele conferred increased odds for GD
compared to controls (OR = 1.33, 95 % CI 1.11–1.59,
p = 1.95 × 10−3); after adjusting for sex and age, the
result remained significant. (OR = 1.28, 95 % CI 1.06–
1.54, p = 9.34 × 10−3). The results suggested this allele
might be a genetic locus of interest for GD, but will
need further confirmation in future studies.
Discussion
This study investigated the genetic associations of GD
using a pooled genome wide association study (GWAS)
in 910 samples. Despite the relatively small number of
samples for discovery GWAS, the pooled strategy in
combination with increased sample size in a second
stage of individual genotyping in both the validation and
replication cohorts, readily detected evidence of associ-
ation of a genetic locus upstream of FCRL3 on chromo-
some 1q23. The association of FCRL3 with GD has
Table 1 Demographics of Graves’ disease cases and controls in the discovery and replication cohorts
N Mean age (SD) Sex
Case Control Case Control p value Graves’ case Controls p value
Discovery cohort 412 498 45.3 (14.5) 56.3 (24.4) <0.001 Male 71 (17.23 %) Male 192 (41.03 %) <0.001
Female 341 (82.77 %) Female 276 (58.97 %)
Replication cohort 539 1230 44.5 (14.8) 48.1 (17.4) <0.001 Male 109 (20.30 %) Male 596 (49.30 %) <0.001
Female 428 (79.70 %) Female 613 (50.70 %)
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previously been identified in large scale GWAS studies
[25, 26, 33]. The pooled GWAS also detected association
of GD with multiple SNPs within the MHC I and MHC
II regions on chromosome 6p21. Susceptibility loci
within both these regions which contain HLA genes in-
volved in antigen presentation, are well established for
GD by association studies, candidate gene analysis and
GWAS [5, 25–27, 44]. Rs9272937 in the un-translated
region of HLA-DQA1 within the MHC class II region
showed evidence of association with GD (p = 4.43 × 10−7)
in our study. The positive association of HLA-DQA1 with
GD has been replicated in multiple studies [15, 44, 45].
Two SNPs within the intron of the C6orf10 gene suggest-
ing association with GD (p 10−7), were also independently
validated as a locus of susceptibility in GD in a previous
GWAS study [26].
These replicative findings in GD prove the robustness of
the two-stage study design for pooled GWAS. The pooled
GWAS study also found evidence of association for a gene
locus marked by rs9644119, downstream of DPYSL2 on
chromosome 8, but the significance is less certain. The
risk attributions from individual genetic variants for GD
are known to be small with odds ratios <1.5, [23] therefore
large sample sizes in the thousands will be needed to in-
crease power for detecting significant association, and
may in the future prove or disprove the significance for
the rs9644119 locus.
For the two compelling signals we have detected in the
vicinity of FCRL3 and DPYSL2, genetic variants in
FCRL3 were associated with a modest increase in odds
for GD at 1.2 to 1.35 [25, 33, 46]. Genetic variation in
the promoter region of FCRL3 i.e. FCRL3 -169T>C allele
is reportedly associated with other autoimmune diseases
such as rheumatoid arthritis and systemic lupus erythe-
matosus, [43, 47, 48] suggesting that the FCRL3 locus
may influence the susceptibility to multiple autoimmune
Table 2 Top ranking SNPs identified from pooled genome wide association study and validation genotyping in the discovery
cohort
GWAS pooled genotyping
(Cases = 412, Controls = 498)
Validation individual genotyping
(Cases = 412, Controls = 480)















T 1.03 × 10−7 1.88 0.101 0.054 1.38 × 10−3 1.91 (1.28, 2.83)
Rs686806 Chr 11q22.3
107228533
CWF19L2 intron T 2.36 × 10−7 1.70 0.242 0.168 9.6 × 10−4 1.53 (1.19, 1.97)
rs62469516 Chr7q21.13
88958624
ZNF804B intron A 2.68 × 10−7 0.51 0.043 0.088 5.73 × 10−5 0.41 (0.26, 0.63)
rs73452600 Chr 7q34
142828104
PIP 1070 bp upstream A 3.49 × 10−7 1.90 0.099 0.061 3.37 × 10−3 1.80 (1.22, 2.67)
Rs1662312 Chr 18p11.31
3220450











T 8.05 × 10−7 1.68 0.254 0.150 1.14 × 10−8 2.05 (1.57, 2.67)
rs28578508 Chr18q12.1
32316007






T 9.82 × 10−7 0.52 0.071 0.141 3.27 × 10−5 0.47 (0.33, 0.67)
Rs3818779 Chr 10q26.11
121140671
GRK5 intron A 1.51 × −6 1.94 0.059 0.029 2.08 × 10−3 2.30 (1.35, 3.9)
rs2141440 Chr 11q14.3
90898463
Intergenic MIR4490 and FAT3 A 4.48 × 10−6 0.58 0.078 0.097 0.34 0.84 (0.59, 1.20)
F_U is individual genotyping minor allele frequency A1 in normal control, F_A is the allele frequency in Graves’ disease
OR is odd ratio for having minor allele in Graves’ cases compared to normal controls
*P values and odds ratios in validation genotyping were adjusted for age and sex
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Table 3 Genotyping results for top ranking single nucleotide polymorphisms in replication cohorts, and combined analysis of discovery and replication cohorts using individual
genotyping
Replication cohorts (Cases = 539, Controls = 1230) Combined discovery and replication cohorts (Cases = 951, Controls = 1710)
SNP name Location chr and bp Gene A1 F_A F_U P value OR_A1 (95 % CI) F_A F_U P value* OR_A1*
Rs9676286 Chr19q13.43
58126481











T 0.096 0.095 0.94 0.99 (0.76–1.29) 0.098 0.083 0.14 1.17 (0.95, 1.44)
Rs686806 Chr 11q22.3
107228533
CWF19L2 intron T 0.198 0.210 0.95 0.99 (0.82, 1.20) 0.217 0.197 0.04 1.63 (1.004, 1.35)
rs62469516 Chr7q21.13
88958624
ZNF804B intron A 0.053 0.053 0.64 1.09 (0.77–1.53) 0.048 0.063 0.06 0.77 (0.59, 1.01)
rs73452600 Chr 7q34
142828104
PIP 1070 bp upstream A 0.090 0.084 0.71 1.05 (0.81, 1.36) 0.094 0.077 0.07 1.22 (0.98–1.50)
Rs1662312 Chr 18p11.31
3220450











T 0.233 0.201 0.04 1.22 (1.01–1.46) 0.242 0.186 3.41 × 10−6 1.42 (1.22, 1.64)
rs28578508 Chr18q12.1
32316007






T 0.094 0.096 0.89 0.98 (0.76, 1.27) 0.084 0.109 9.45 × 10−3 0.76 (0.62, 0.93)
Rs3818779 Chr 10q26.11
121140671
GRK5 intron A 0.055 0.049 0.58 1.10 (0.78, 1.55) 0.057 0.043 0.06 1.31 (0.99, 1.72)
rs2141440 Chr 11q14.3
90898463
Intergenic MIR4490 and FAT3 A 0.094 0.086 0.53 1.09 (0.84, 1.41) 0.087 0.089 0.88 0.98 (0.80, 1.21)













diseases in a similar manner to the immune regulating
CTLA4, PTPN22 and MHC genes [24, 25, 32]. To pin-
point the exact locus associated with FCRL3, the entire
FCRL region on chromosome 1q21 was previously inves-
tigated using imputation, and the strongest signals asso-
ciated with GD were located in a cluster of SNPs
including rs7528684 and rs3761959 [49]. SNP rs7528684
in the promoter region of FCRL3 was also previously re-
ported as positively associated with rheumatoid arthritis,
systemic lupus erythematosus and GD [43]. Rs3761959
tagging rs7522061 and rs7528684 in the FCRL3 gene
showed association with GD in the Wellcome Trust
Case Control Consortium GWAS study (p = 9.4 × 10−3),
and the association was further confirmed by The
China Consortium for the Genetics of Autoimmune
Thyroid disease, reaching genome wide significance
(p = 2.22 × 10−8) [25, 33]. In addition, rs11264798 in
FCRL3 was also associated with GD (p = 1.6 × 10−5)
[25]. We found high linkage disequilibrium of rs17676303,
the SNP associated with GD in our study, with rs7528684,
rs3761959 and rs11264798, that strongly suggest these
SNPs were tagging the same functional variants in the
vicinity of the FCRL3 gene.
Functional analysis suggests FCRL3 has immune regu-
lating roles. FCRL3 is an Fc receptor like molecule that
shares a genomic location (chr 1q21-23) and gene struc-
ture as a receptor for the Fc portion of immunoglobulin
with other members of the immunoglobulin superfamily
[50]. Unlike the Fc receptor, the FCRL molecule has not
been shown biochemically to bind immunoglobulin [50].
FCRL3 molecules are preferentially expressed by B cells
[51, 52]. FCRL3 possesses both tyrosine based activating
and inhibitory motifs in its cytoplasmic tail, indicating
these may be used to transmit immune-modulatory sig-
nals via tyrosine phorphorylation in regulating B cell dif-
ferentiation and response [50]. The strongest evidence
linking FCRL3 polymorphisms with autoimmunity is de-
rived from linkage disequilibrium mapping of the
chr1q21-23 region in rheumatoid arthritis, which identi-
fied 4 SNPs (rs7528684, rs11264799, rs945635 and
rs3761959) in a Japanese population [43]. Of the 4 SNPs
positively associated with rheumatoid arthritis, FCRL3
-169T>C (marked by rs7528684 in the promoter region
of FCRL3) substitution substantially increased promoter
activity in FCRL3 and enhanced binding affinity to the
consensus NF-κβ binding motif, where NF-κβ widely
regulates genes involved in immune response [43]. In
addition, FCRL3 transcripts in peripheral B cells and
genomic DNA are higher in heterozygous individuals
with genotype -169C/T +358C/G, and increased FCRL3
expression in synovial tissue and peripheral CD19+ B
cell population suggest that higher expression of FCRL3
is potentially pathogenic [43]. Further correlation of B
cell abnormalities with FCRL3 expression is afforded by
significant positive correlation of rheumatoid factor
autoantibody titre in individuals with rheumatoid arth-
ritis with the number of susceptible −169 C alleles [43].
However not all studies showed consistent association
with polymorphisms in FCRL3, specifically no discern-
ible association with FCRL3 were noted in some other
rheumatoid arthritis populations including Caucasians in
North American and European countries [53–55]. When
the susceptibility effect of FCRL3 was stratified by
NF-κβ1 genotypes, association of FCRL3 polymor-
phisms with rheumatoid arthritis was observed in
patients heterozygous for the NF-κβ1 promoter in a
Spanish population [54].
The second gene of interest, DPYSL2, produces collap-
sin response mediator protein 2 (CRMP2). It was first
described in the central nervous system as an effector
cytosolic protein for semaphorin mediated axonal
growth cones navigation during neural development and
plasticity [56]. Dysregulation of CRMP2 phosphorylation
and expression, have been associated with neuropsychi-
atric diseases including Alzheimer’s disease and schizo-
phrenia [56]. CRMP2 is also highly expressed in activated
T lymphocytes from peripheral blood bearing CD69 and
HLA-DR markers. CRMP2 is distributed in the trailing
uropod in polarized T cells binding to cytoskeletal struc-
tures particularly to vimentin [57]. The observations of
enhanced spontaneous and chemokine-directed T cell
transmigration by induced expression of CRMP2 in Jurkat
T cells, and high expression of CRMP2 in migrating T cells
suggest CRMP2 may regulate T cell motility and migration
[57]. The mechanism underlying CRMP2 induced T
cell migration seems to involve phosphorylation of
CRMP2 Tyr-479 residue, acting as transducer for che-
mokine stromal cell-derived factor-1α (CXCL12) sig-
naling [58]. The discovery of CRMP2 cellular function
in T cells defines its potential role in the pathogenesis
of immune mediated inflammation, specifically neuro-
inflammation [59].
Table 4 Haploview linkage disequilibrium between known susceptibility loci in Graves’ disease and rs17676303 identified in pooled
GWAS for Graves’ disease in Hapmap CEU population data
Locus 1 Locus 2 D’ Log of the Odds (LOD) R2 CI low CI High
rs11264798 rs17676303 1.0 4.44 0.142 0.64 1.0
rs3761959 rs17676303 1.0 5.83 0.221 0.71 1.0
rs7528684 rs17676303 1.0 5.73 0.224 0.7 1.0
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Conclusions
In conclusion, the pooled GWAS is an effective method-
ology for detecting common genetic variants in GD. The
study confirmed FCRL3 region as a susceptibility locus
for GD in addition to MHC. A second locus down-
stream of DPYSL2 is potentially a novel genetic variant
in GD that requires further confirmation.
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is high r = 0.89. (TIF 9765 kb)
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